Overview
Insight Economics experts provided comprehensive economic analysis and expert testimony in a high-profile Delaware federal case between TwinStrand Biosciences, the University of Washington, and Guardant Health. The dispute centered around damages relating to advanced DNA sequencing patents for cancer detection. Insight’s work informed a jury verdict awarding $83.4 million in damages following a five-day trial.

Challenge
The case required rigorous assessment of the economic impact associated with patented DNA sequencing technologies. Insight was tasked with analyzing the commercial value, financial impact, and damages incurred by the asserted patents. The team collaborated with legal counsel to present compelling, data-driven analysis in Federal Court.

Results
Insight Economics delivered expert opinions and clear economic evidence that supported the damages calculation adopted by the jury. Their analysis contributed significantly to the client’s ability to recover substantial compensation in the form of an $83.4 million verdict. The trial outcome demonstrated the value of Insight’s financial models and testimony in complex intellectual property litigation.